ELRiSE MDS
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 300 patients (estimated)
- Tags
- Activin Receptor IIA Inhibitor, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2232
- NCT Identifier
- NCT07422480
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.